免疫反应。这些复制子应为使用钝化疫苗，因为它们不能引起在宿主和它们应该比使用未钝化疫苗因为它们可以复制在宿主。

应用程序：防止严重的和/或致命的疾病造成的病毒，主要健康关心在热带和亚热带地区。

发明人：Xiaowu Pang (CBER/FDA)。
专利状况：US专利申请10/656,721于2003年03月05日，优先权日3月09日2001年（HHS参考号E-228–2000/0–US–03）。
许可状况：可用非独家或独家许可。
许可联系人：Peter A. Soukas, J.D.; 301/435-4646; soukas@mail.nih.gov。
日期：2006年1月1日。
Steven M. Ferguson,
主任，技术发展和转让，办公室技术转让，国家健康研究所。

[FR Doc. E-21009 Filed 12–11–06; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

国家健康研究所

政府拥有发明；可用性许可

机构：国家健康研究所，公共健康服务，HHS。

行动：注意。

总结：列出的发明是被所有拥有的版权的U.S.政府，并是可得在没有联邦的资助研究和发展的。外国专利申请是在为选择的发明扩展市场可得的，公司和也可在共同的为许可。

地址：许可信息和副本的美国专利申请列表以下是可能在被分配给由通告到许可联系人，办公室技术转让，国家健康研究所，6011Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; 电话：301/496–7057; 传真：301/402–0220。一个签署的机密性讨论协议将被要求来接收副本的专利申请。

ARH3，一个治疗性目标为癌症、缺血和炎症

描述技术：ADP-riboseylation是重要的在许多细胞过程，包括DNA复制和修复，保持的基因组稳定性，细胞分化和增殖，凋亡和凋亡。Poly-ADP-ribose在是一种在许多的细胞生理过程如DNA修复，细胞分化，和凋亡。Poly-ADP-ribose，一种ADP-ribose的类似物，是通过一种被识别为导致ADP-ribose的聚合物。另一个ADP-ribose，O-acetyl-ADP-ribose，被通过被影响到的deacetylation，如acetyl-histone，由蛋白质在Sir2家庭。Sir2蛋白质被在调节染色质结构和长寿影响。

NIH宣布发现一个PARG-like酶，ARH3。ARH3具有PARG活性，且是结构上不同的PARG。ARH3也水解O-acetyl-ADP-ribose，且是唯一的蛋白质被识别为与这种活性。ARH3似乎在影响两种重要的信号通路，服务于调节两种poly-ADP-ribose和O-acetyl-ADP-ribose两个途径。这些药物可能被用作抗肿瘤剂，放射敏感剂或抗病毒的，或为处理通路涉及氧化性损伤，如急性组织损伤，缺血和炎症。

应用程序：(1) TB治疗的通路为癌和通路的多余DNA损伤；(2) TB治疗的通路为疾病涉及氧化性损伤，如急性组织损伤，缺血和炎症。

市场：(1) 急性组织损伤，缺血，和炎症的患者；(2) 接触化疗的抗肿瘤剂，或与癌症是基因上够的DNA修复的患者。


许可状况：可用非独家或独家许可。
许可联系人：Tara L. Kirby, PhD; 301/435–4033; tarak@mail.nih.gov。

协作研究机会：国家心肺血管研究所的肺科护理医学的支气管在国家的心肺血管，肺和血学研究是声明的能力或从注意的在商业化的研究为更进一步发展，开发，或商业化的许可证。请与Marianne Lynch在NHLBI办公室技术转让和开发的电话（301–594–4094）或e-mail（lynchn@nihbi.gov）为更多的信息。

抗血清检测磷酸化磷脂二醇依赖性蛋白激酶1

描述技术：PDK–1磷酸化和激活一种细胞外基质的，和在作为主要的角色来于控制生和生长因子的信号传递。PDK–1也代表一个有希望的药物目标为的几种癌症。在Ser244的（小鼠）或Ser241（人）是PDK–1的有期待的抗血清。

可用性：可用多克隆抗血清为筛查PDK–1的磷酸化抑制剂为癌症和其它的指示的；(2) 为研究肾素和生长因子的信号传递。

发明人：Michael J. Quon (NCCAM)。

专利状况：HHS参考号E–330–2003/0–Research Tool。
许可状况：这个技术是可用为一个研究工具在一个生物材料的许可证。
许可联系人：Tara L. Kirby, PhD; 301/435–4426; tarak@mail.nih.gov。
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Library of Medicine; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The portions of the meeting devoted to the review and evaluation of journals for potential indexing by the National Library of Medicine will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended. Premature disclosure of the titles of the journals as potential titles to be indexed by the National Library of Medicine, the discussions, and the presence of individuals associated with these publications could significantly frustrate the review and evaluation of individual journals.

Name of Committee: Literature Selection Technical Review Committee.


Open: February 22, 2007, 9 a.m. to 11 a.m. Agenda: Administrative reports and program discussions.

Place: National Library of Medicine, Building 38, Board Room, 2nd Floor, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 22, 2007, 11 a.m. to 5 p.m.

Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine.

Place: National Library of Medicine, Building 38, Board Room, 2nd Floor, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 23, 2007, 8:30 a.m. to 2 p.m.

Agenda: To review and evaluate journals as potential titles to be indexed by the National Library of Medicine.

Place: National Library of Medicine, Building 38, Board Room, 2nd Floor, 8600 Rockville Pike, Bethesda, MD 20894.

Closed: February 23, 2007, 8:45 a.m. to 2 p.m.

SUPPLEMENTARY INFORMATION: On September 28, 2006 at 71 FR 56999. Copies of that notice, as well as this notice are available electronically by searching for docket number USCG–2006–25522 at http://dms.dot.gov. The purpose of the physical examination notice was to implement the recommendation made by the National Transportation Safety Board (NTSB), in their report on the 2003 allision of the Staten Island Ferry ANDREW J. BARBERI, that the Coast Guard require submission of annual pilot physicals. This notice is a continuation of the Coast Guard’s efforts to fully implement the NTSB’s recommendation.

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[USCG 2006–25522]

Exercise of Authority To Require Pilots To Submit Results of Annual Chemical Test for Dangerous Drugs and Extension of Deadline for Pilots To Submit Most Recent Annual Physical Examination

ACTION: Notice.

SUMMARY: By this notice, the Coast Guard is exercising authority currently set forth in Coast Guard regulations to require all first class pilots on vessels greater than 1600 GRT, and those individuals who “serve as” pilots in accordance with 46 CFR 15.812(b)(3) & (c) on vessels greater than 1600 GRT, to submit copies of their annual physical examinations to the Coast Guard, 71 Fed. Reg. 56999. Copies of that notice, as well as this notice are available electronically by searching for docket number USCG–2006–25522 at http://dms.dot.gov. The purpose of the physical examination notice was to implement the recommendation made by the National Transportation Safety Board (NTSB), in their report on the 2003 allision of the Staten Island Ferry ANDREW J. BARBERI, that the Coast Guard require submission of annual pilot physicals. This notice is a continuation of the Coast Guard’s efforts to fully implement the NTSB’s recommendation.

Coast Guard regulations require that, unless excepted under 46 CFR 16.220(c), each pilot who is required to complete an annual physical examination must also pass a chemical test for dangerous drugs, and that he or she must submit the passing (i.e. negative) results of the chemical test to the Coast Guard when applying for license renewal, or when requested by the Coast Guard. 46 CFR 16.220(b). This includes first class pilots on vessels greater than 1600 GRT, and those individuals who “serve as” pilots in accordance with 46 CFR 15.812(b)(3) &